|Institute for Research & Innovation|
- Institute for Research & Innovation
- About Us
- Participate in a Study
- Become an Investigator
- Information for Sponsors
Multiple Sclerosis - Relapse (Ages 18-55)Title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis
Purpose: This study is seeking patients who have clinically diagnosed Multiple Sclerosis with at least 2 documented clinical attacks (relapses) within the last 2 years. This study is comparing Ocrelizumab to Rebif.
Who Can Participate? Patients who meet the relapse criteria listed above. Medication restrictions may apply depending of what type of MS modifying therapy you are currently using.
Diagnosis or Condition: Patients with a clinical diagnosis of Multiple Sclerosis
Medication: Investigational Product is delivered via IV infusion every 6 months.
Age: Between 18 and 55 years of age
Sex: Males and Females
Visits: Patients will be followed for up to 96 weeks and includes 4 infusion treatment cycles every 6 months
Stipend: You will be compensated for your time and travel
Principal Investigator(s): John Huddlestone, MD, FAAN
Study Coordinator: Andrea Thompson, 253-403-7440